logo

Citius Pharmaceuticals, Inc. (CTXR)



Trade CTXR now with
  Date
  Headline
2/17/2021 12:36:15 AM Citius Pharmaceuticals Announces $76.5 Mln Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/9/2020 9:44:23 AM Citius : FDA Grants Written Response Only Meeting Regarding Guidance And Direction On The Mino-Wrap Development Plan
10/13/2020 7:38:23 AM Novellus Therapeutics Licenses Induced MSCs To NoveCite For COVID-19 Related ARDS, Other Acute Respiratory Conditions
10/7/2020 7:06:57 AM Citius Pharma Signs Worldwide Licensing Agreement With Novellus Therapeutics For Unique IMSC-Therapy
9/29/2020 10:20:34 AM Citius Reports Positive Results From Recent Data Monitoring Committee Meeting For Mino-Lok Phase 3 Trial
9/22/2020 8:20:59 AM Citius Pharmaceuticals Achieves Number Of Significant Milestones Over Past Several Weeks For Mino-Lok
9/15/2020 10:20:42 AM Citius Files Addendum To Mino-Lok Phase 3 Trial Record Keeping Protocol To Advance Trials With COVID-19 Compliance
8/4/2020 8:20:08 AM Citius Says Submits Mino-Wrap Briefing Package To FDA For Pre-IND Consult
7/22/2020 10:34:33 AM Citius Forms Board For Development Of Proprietary Treatment For Acute Respiratory Disease Associated With COVID-19
7/14/2020 8:54:28 AM Myron Czuczman Joins Citius As Chief Medical Officer And EVP
7/13/2020 8:16:08 AM Citius Pharma Regains Compliance With Nasdaq Listing Requirements
6/26/2020 9:08:32 AM Citius Gets FDA Response On PIND Application For Its IMSCs To Treat ARDS In Patients With COVID-19; Stock Surges
6/2/2020 9:31:54 AM Citius Gets Positive FDA Feedback On Submitted Plan To Study Catheter Compatibility For Mino-Lok Therapy
5/26/2020 8:18:07 AM Citius Provides Free Access To Mino-Lok For Healthcare Providers